After to a split advisory committee vote last month on Chiron Corp.'s Pulminiq, the FDA issued an approvable letter but asked for another study to confirm efficacy of the lung transplant drug. (BioWorld Today)

A little more than two months after filing for approval of Vivitrex, Alkermes Inc. partnered the alcohol-dependence drug with Cephalon Inc. in a 50-50 profit-sharing deal worth an additional $480 million in up-front and milestone payments. (BioWorld Today)